Our pipeline is comprised of several novel drug candidates including JAK2V617F mutant selective inhibitors and highly selective KAT6A degraders. We are also leveraging our expertise in targeted protein degradation to discover and develop next generation degrader antibody conjugates (DACs).
We are developing a diverse pipeline of first-in-class agents for hard-to-treat cancers with high unmet need.
| Program | Potential Indications | Discovery/Lead Opt. | IND-Enabling | Phase 1 | Program Interest | Upcoming Milestones |
|---|---|---|---|---|---|---|
| PR-01 | ||||||
| JAK2V617F Mutant Selective JH2 Inhibitors |
VF+ myeloproliferative neoplasms (MPNs) (MF, PV, ET) |  | IND filing Q1 2026 Oral abstract at ASH 2025 | |||
| KAT6A Selective Degraders | ER+ breast cancer, other malignancies | Prelude wholly owned | IND filing mid-2026 | |||
| mCALR DAC |
CALR-mutated MPNs (ET, MF) | Prelude wholly owned | Oral abstract at ASH 2025 | |||
| Degrader Payloads for DACs | Broad utility across multiple indications |  | Additional Partnerships | |||
| PR-01 | JAK2V617F Mutant Selective JH2 Inhibitors | |
| VF+ myeloproliferative neoplasms (MPNs) (MF, PV, ET) | ||
Discovery/Lead Opt. IND-Enabling Phase 1 | ||
| Upcoming Milestones: IND filing Q1 2026 Oral abstract at ASH 2025 | ||
| KAT6A Selective Degraders Prelude wholly owned | ||
| ER+ breast cancer, other malignancies | ||
Discovery/Lead Opt. IND-Enabling Phase 1 | ||
| Upcoming Milestones: IND filing mid-2026 | ||
| mCALR DAC Prelude wholly owned | ||
| CALR-mutated MPNs (ET, MF) | ||
Discovery/Lead Opt. IND-Enabling Phase 1 | ||
| Upcoming Milestones: Oral abstract at ASH 2025 | ||
| Degrader Payloads for DACs | ||
| Broad utility across multiple indications | ||
Discovery/Lead Opt. IND-Enabling Phase 1 | ||
| Proprietary degrader payloads available for licensing to partners developing next generation DACs Additional Partnerships | ||
JAK2, janus kinase 2; JH2, JAK2 homology domain 2 (pseudokinase regulatory domain); VF+, V617F mutated; MPNs, myeloproliferative neoplasms; MF, myelofibrosis;
PV, polycythemia vera; ET, essential thrombocythemia; ER+, estrogen receptor positive; DAC, degrader antibody conjugate; mCALR = mutated calreticulin
1 – Exclusive option agreement with Incyte (announced November 2025)
2 – DAC Discovery Collaboration with AbCellera (announced November 2023, amended and expanded 2H 2025)